342 filings
Page 9 of 18
8-K
mov nubb5c
8 May 09
Ariad Reports First Quarter 2009 Development Progress and Financial Results
12:00am
8-K
o1w81wgjlwvr1
21 Apr 09
Other Events
12:00am
8-K
m5r04n
20 Apr 09
Preclinical Data Presented on ARIAD’s Investigational mTOR Inhibitor, Deforolimus, in Lung Cancer and Other Solid Tumor Models
12:00am
8-K
l6168flfehdq 7xc8b
8 Apr 09
ARIAD Appoints Former Bristol-Myers Squibb Senior Executive as New Independent Member of Its Board of Directors
12:00am
8-K
oddxtpna
8 Apr 09
ARIAD Announces Court Rulings Regarding NF-κB Patent Lawsuit with Lilly
12:00am
8-K
9z7efzdc006ol3jk
16 Mar 09
Departure of Directors or Certain Officers
12:00am
8-K
lpfxhbp3
20 Feb 09
Ariad Announces $24.3 Million Registered Direct Financing
12:00am
8-K
og8dhfsd
17 Feb 09
Other Events
12:00am
8-K
7j6yiac l84h3uz
12 Feb 09
Results of Operations and Financial Condition
12:00am
8-K
dxono
16 Jan 09
ARIAD Announces 2009 Key Corporate Objectives
12:00am
8-K
wpdcti6t
12 Dec 08
ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Inhibition of All Known Variants of the CML Target Protein Bcr-Abl
12:00am
8-K
09ddy8ar4e6 s57ff
5 Dec 08
Departure of Directors or Principal Officers
12:00am
8-K
4w16 woad6o
6 Nov 08
ARIAD Reports Third Quarter 2008 Financial Results and Development Progress
12:00am
8-K
utvyf6ydt18
5 Nov 08
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
fbt4 s4iziyxn07
27 Oct 08
ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Mechanism-Based Activity in Solid Tumors
12:00am
8-K
uzd88
23 Oct 08
ARIAD Presents Preclinical Data on Deforolimus and Bicalutamide in Androgen-Independent Prostate Cancer
12:00am
8-K
kljfy22
21 Oct 08
Departure of Directors or Principal Officers
12:00am
8-K
38mav7no
20 Oct 08
Ariad Announces Start of Phase 2 Clinical Study of Oral Deforolimus in Patients with Prostate Cancer
12:00am
8-K
z5qregb6a9wh
15 Oct 08
Departure of Directors or Principal Officers
12:00am
8-K
clzj04i
7 Oct 08
Ariad Appoints Two New Members to Its Board of Directors
12:00am